BACKGROUND: Recent studies questioning the benefit of prostate-specific antigen (PSA) screening have increased the need for evaluating factors contributing to variance in levels and their clinical relevance. An inverse relationship between body mass index (BMI) and PSA has been illustrated, however the clinical implications have not been specified. We performed a retrospective review of patients screened through our free screening clinic to delineate any relationship between PSA and BMI in an attempt to understand its possible clinical significance. METHODS: The authors retrospectively reviewed data collected in relation to PSA values and patient characteristics from a community outreach program supplying information and screening for prostate cancer between June of 2003 and August of 2009. RESULTS: Mean BMI of our patient population was 28.7 m/kg(2) (SD 5.4) and our mean PSA value was 1.28 (SD 1.77). Our data indicate a small, but statistically significant decrease in PSA for an increasing BMI with a 0.026 decrease in PSA for every unit increase in BMI. CONCLUSIONS: Our study confirms the previously reported inverse relationship between PSA value and BMI. The significance of this finding and its impact on the value do not seem to indicate a rationale to change the accepted abnormal value in obese patients and should be used in the context of the clinical scenario and other PSA altering factors.
BACKGROUND: Recent studies questioning the benefit of prostate-specific antigen (PSA) screening have increased the need for evaluating factors contributing to variance in levels and their clinical relevance. An inverse relationship between body mass index (BMI) and PSA has been illustrated, however the clinical implications have not been specified. We performed a retrospective review of patients screened through our free screening clinic to delineate any relationship between PSA and BMI in an attempt to understand its possible clinical significance. METHODS: The authors retrospectively reviewed data collected in relation to PSA values and patient characteristics from a community outreach program supplying information and screening for prostate cancer between June of 2003 and August of 2009. RESULTS: Mean BMI of our patient population was 28.7 m/kg(2) (SD 5.4) and our mean PSA value was 1.28 (SD 1.77). Our data indicate a small, but statistically significant decrease in PSA for an increasing BMI with a 0.026 decrease in PSA for every unit increase in BMI. CONCLUSIONS: Our study confirms the previously reported inverse relationship between PSA value and BMI. The significance of this finding and its impact on the value do not seem to indicate a rationale to change the accepted abnormal value in obesepatients and should be used in the context of the clinical scenario and other PSA altering factors.
Authors: David M Werny; Trevor Thompson; Mona Saraiya; David Freedman; Benny J Kottiri; Robert R German; Mark Wener Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12-19 Impact factor: 4.254
Authors: Grace Lu-Yao; Peter C Albertsen; Janet L Stanford; Therese A Stukel; Elizabeth Walker-Corkery; Michael J Barry Journal: J Gen Intern Med Date: 2008-09-16 Impact factor: 5.128
Authors: Jacques Baillargeon; Brad H Pollock; Alan R Kristal; Patrick Bradshaw; Javier Hernandez; Joseph Basler; Betsy Higgins; Steve Lynch; Thomas Rozanski; Dean Troyer; Ian Thompson Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Lionel L Bañez; Robert J Hamilton; Alan W Partin; Robin T Vollmer; Leon Sun; Carmen Rodriguez; Yiting Wang; Martha K Terris; William J Aronson; Joseph C Presti; Christopher J Kane; Christopher L Amling; Judd W Moul; Stephen J Freedland Journal: JAMA Date: 2007-11-21 Impact factor: 56.272
Authors: June Hyun Han; In Ho Chang; Seung Hyun Ahn; Oh Jung Kwon; Seong Hak Bang; Nak Young Choi; Sang Wook Park; Soon Chul Myung; Hyun Woo Kim Journal: BJU Int Date: 2008-06-03 Impact factor: 5.588
Authors: Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: A S Parker; D D Thiel; E Bergstralh; R E Carlson; L J Rangel; R W Joseph; N Diehl; R J Karnes Journal: Prostate Cancer Prostatic Dis Date: 2013-08-20 Impact factor: 5.554
Authors: Sean Harrison; Kate Tilling; Emma L Turner; J Athene Lane; Andrew Simpkin; Michael Davis; Jenny Donovan; Freddie C Hamdy; David E Neal; Richard M Martin Journal: Cancer Causes Control Date: 2016-11-09 Impact factor: 2.506
Authors: Sean Harrison; Kate Tilling; Emma L Turner; Richard M Martin; Rosie Lennon; J Athene Lane; Jenny L Donovan; Freddie C Hamdy; David E Neal; J L H Ruud Bosch; Hayley E Jones Journal: Cancer Causes Control Date: 2020-03-11 Impact factor: 2.506
Authors: Christopher Goßler; Matthias May; Bernd Rosenhammer; Johannes Breyer; Gjoko Stojanoski; Steffen Weikert; Sebastian Lenart; Anton Ponholzer; Christina Dreissig; Maximilian Burger; Christian Gilfrich; Johannes Bründl Journal: Cent European J Urol Date: 2020-12-03